news
First European ustekinumab biosimilar to Stelara approved
The first biosimilar to Stelara® is now approved in Europe, a biologic therapy with indications across gastroenterology, dermatology, and rheumatology.
List view / Grid view
Stelara (ustekinumab)
news
Sandoz to commercialise mAb biosimilar candidate
A new commercialisation agreement between Sandoz and Samsung Bioepis’ for its ustekinumab biosimilar candidate, means Sandoz now has five potential high-value biosimilars anticipated to launch over the next two years.
news
Stelara® “a compelling option” for the treatment of Crohn’s disease
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC).
news
EC approves ustekinumab to treat plaque psoriasis in patients age six to 11
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
article
EPR’s news round-up 2019: the stories that defined the year
This article highlights the 10 most popular news stories published by European Pharmaceutical Review in 2019.
article
Treating ulcerative colitis with a safe and effective biologic
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
EC approves expanded use of ustekinumab for ulcerative colitis
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
news
Janssen announces FDA approval of Stelara for plaque psoriasis
The FDA has approved an expanded indication for Stelara for the treatment of adolescents with moderate plaque psoriasis...
news
Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
news
Stelara induces clinical remission in Crohn’s disease in Phase 3 trial
20 October 2015 | By Victoria White
New Phase 3 data show treatment with Janssen’s Stelara (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn's disease who had previously failed conventional therapy.
